doi: 10.1016/S0002-9343(01)00642-8. LOKELMA Savings, Coupons and Information. -, Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Visit Website. Background and objective: Lokelma's primary brand-name competitor, Veltassa (patiromer) had a black box warning about drug interactions, which was removed in 2016. Utility estimates and costs were derived from the literature and list prices. VELTASSA is not absorbed by the body. Storing VELTASSA. Lokelma Co-pay Savings Card: Eligible commercially insured patients may pay as low as $0 per prescription with savings of up to $250 per 30-packet supply; for additional information contact the program at 844-565-3562. AZ paid $2.7 billion to acquire Lokelma’s developer, ZS Pharma, in 2015 in the hope that the drug could soon start on a journey to $1 billion-plus in peak sales. Unable to load your collection due to an error, Unable to load your delegates due to an error, Markov model for heart failure (HF). Administer other oral medications at least 3 hours before or 3 hours after Veltassa and 2 hours before or 2 hours after Lokelma (1-2). doi: 10.1002/pds.3748. A Markov model was constructed to simulate a cohort of 65-year-old patients diagnosed with HF from the payer perspective across the lifetime horizon. Participants will complete a symptom and palatability questionnaire at 4 hours. Monitor serum potassium and adjust the dose of Veltassa based on the serum potassium level and the desired target range. -, Schepkens H, Vanholder R, Billiouw J-M, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Prevention and treatment information (HHS). It is used to treat too much potassium in the body. -, Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. ESC Heart Fail. The cost for Lokelma oral powder for reconstitution 5 g is around $281 for a supply of 11 powder for reconstitution, depending on the pharmacy you visit. COVID-19 is an emerging, rapidly evolving situation. Eligibility determined on a case-by-case basis. The free Drugs.com Discount Card works like a coupon and can save you up to Nina Oestreicher reports previous employment by Relypsa, Inc., a Vifor Pharma Group Company at the time of the study. Chantal M. Dolan and Kathryn A. Fisher are employees of CMD Consulting, and report consulting relationships with Genentech Inc., Gilead Sciences, Halozyme Therapeutics, Iconic Therapeutics, Semnur Pharmaceuticals and Relypsa, Inc., a Vifor Pharma Group Company. 1999;341:709–717. Lokelma Free Trial Offer: Eligible patients may receive one 30-day supply for FREE; for additional information contact the program at 866-494-8080. Think of Lokelma (sodium zirconium cyclosilicate) and Veltassa (patiromer) as similar to sodium polystyrene sulfonate (Kayexalate, etc) or calcium polystyrene sulfonate (Resonium Calcium). The dose may be increased or decreased, as necessary, to reach the desired serum potassium concentration, up to a maximum dose of 25.2 grams once daily. LOKELMA can cause swelling (edema) caused by fluid retention in your body (such as hands, ankles, feet). Careers. Am Health Drug Benefits. More information please phone: Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions. Eligibility requirements vary for each program. The starting dose is 8.4 g daily, which is increased weekly based on … 2015;24:406–413. AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. Epub 2018 Jan 25. SZC (Lokelma). Paul J. Hauptman reports consultant/advisory board fees, research grants, and speaker/honoraria from Relypsa, Inc., a Vifor Pharma Group Company. Treatment with patiromer-spironolactone-ACEI was projected to increase longevity compared with ACEI alone (5.29 vs. 4.62 life-years gained, respectively), greater QALYs (2.79 vs. 2.60), and costs (US$28,200 vs. US$18,200), giving an ICER of US$52,700 per QALY gained. Javed Butler reports consultancy/advisory board fees from Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, Inc., a Vifor Pharma Group Company, Stealth Peptide, SC Pharma, Vifor, and ZS Pharma; other research support and research grants from European Union and the National Institutes of Health; and speaker/honoraria from Novartis and Janssen. However, if they are accepted into the LIS, they are no longer eligible for the AZ& Me Prescription Savings Program. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. $595.0013 ($19.83/day) $1,785.00 ($59.50/day) KayexalateTM. doi: 10.1056/NEJM199909023411001. LOKELMA contains 400 mg of sodium in each 5 g dose. Co-Pay Range$12 – $1033. U54 GM115428/GM/NIGMS NIH HHS/United States, eScholarship, California Digital Library, University of California, NCI CPTC Antibody Characterization Program, Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. Desai NR, Reed P, Alvarez PJ, Fogli J, Woods SD, Owens MK. 21st May 2018. 2005;30:603–610. Here are 10 ways to save money on prescription drugs, sodium bicarbonate, Kayexalate, insulin regular, calcium gluconate, Humulin R, Veltassa. Cost Analysis*. Patiromer is a novel agent used to treat hyperkalemia and has been shown to be efficacious, safe, and well-tolerated. The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population. The ICERs ranged from US$40,000 to US$85,800 per QALY gained in 1-way sensitivity analyses. ESC Heart Fail. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. Lokelma (sodium zirconium cyclosilicate or ZS-9) has been approved for adults with hyperkalaemia, a potentially life-threatening condition which can cause cardiac arrest and muscle paralysis, allowing it to finally challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. It is available as a powder that is mixed with water prior to administration. Drug. Clinical inputs were derived from the RALES and OPAL-HK randomized trials of spironolactone and patiromer, respectively. Long-term outcome benefit in this patient population, or for the treatment of hyperkalemia in ... for hyperkalemia and the cost of addition of a medication to manage hyperkalemia. Lokelma (sodium zirconium cyclosilicate) Jeffrey A. Dunn reports consultancy/advisory board fees from Relypsa, Inc., a Vifor Pharma Group Company. In placebo-controlled trials in which patients who were not on dialysis were treated with once daily doses of LOKELMA for up to 28 days, edema was reported in 4.4% of patients receiving 5 g, 5.9% of patients receiving 10 g and 16.1% of patients receiving 15 g LOKELMA compared to 2.4% of patients receiving placebo. AstraZeneca bought Lokelma's maker in 2015 but could not ramp up drug production until 2018. 844-275-2360 The circles represent health states, and each arrow represents a possible transition from one state to another. Bethesda, MD 20894, Copyright This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Lokelma and Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M; Patiromer-204 Investigators. Again, this study showed improved rate of normokalemia in the Lokelma group vs. placebo in days 3-14. Tornado diagram of the incremental cost-effectiveness ratios changes between the patiromer–spironolactone–ACEI strategy and ACEI-only strategy. Our results suggest that the use of spironolactone-patiromer-ACEI may provide clinical benefit and good economic value in patients with NYHA class III-IV HF unable to tolerate spironolactone due to hyperkalemia. Am J Manag Care. But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. Available for Android and iOS devices. 2018 Jun;5(3):257-266. doi: 10.1002/ehf2.12265. Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives. Visit Website, More information please phone: (sodium zirconium cyclosilicate) Epub 2015 Nov 19. The green line represents the willingness-to-pay threshold of US$100,000 per…, National Library of Medicine The actual price you’ll pay for either drug depends on your … The patient must also be a US resident, green card or work visa holder. Third time's the charm for AstraZeneca’s blockbuster hopeful Lokelma, formerly known as ZS-9 … Eligibility determined on a case-by-case basis. 1958. Pharmacoeconomics. Results: Treatment with patiromer-spironolactone-ACEI was projected to increase longevity compared with ACEI alone (5.29 vs. 4.62 life-years gained, respectively), greater QALYs (2.79 vs. 2.60), and costs (US$28,200 vs. US$18,200), giving an ICER of US$52,700 per QALY gained. Clipboard, Search History, and several other advanced features are temporarily unavailable. Blood potassium will be checked at 2 and 4 hours after dose of study drug. Visit Website, More information please phone: Data sources include IBM Watson Micromedex (updated 3 Mar 2021), Cerner Multum™ (updated 1 Mar 2021), ASHP (updated 3 Mar 2021) and others. Mark Bounthavong and David L. Veenstra report consulting relationships with Relypsa, Inc., a Vifor Pharma Group Company. Lokelma (sodium zirconium cyclosilicate) is a member of the cation exchange resins drug class and is commonly used for Hyperkalemia. We comply with the HONcode standard for trustworthy health information -, Here are 10 ways to save money on prescription drugs. 2018 Aug;5(4):592-602. doi: 10.1002/ehf2.12292. Patiromer (Veltassa), approved in 2015, is a nonabsorbed polymer that binds potassium in the gastrointestinal (GI) tract. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. Trial Data Confirm: Veltassa, Lokelma Effective for Hyperkalemia — But agents' long-term safety and efficacy not yet established. -, Abbas S, Ihle P, Harder S, Schubert I. | SODIUM ZIRCONIUM CYCLOSILICATE (SOE dee um zir KOE nee um SYE kloe SIL i kate) takes potassium out of the body by binding to it in the intestines. eCollection 2019. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. 866-316-7263 The indifference point between the patiromer–spironolactone–ACEI arm and the ACEI-only arm is the reported incremental cost-effectiveness ratio. Cost-effectiveness acceptability curve. -. Background: Lokelma and Veltassa are indicated for the treatment of hyperkalemia. In placebo-controlled trials up to 28 days, edema was reported in 4.4%, 5.9%, 16.1% of non-dialysis patients treated with 5 g, 10 g, and 15 g of LOKELMA once daily, respectively vs 2.4% of non-dialysis patients receiving placebo. Please enable it to take advantage of the complete set of features! *In a 52-week clinical study, up to 95% of people taking VELTASSA reduced their potassium levels and kept them normal over time (3.8 to <5.1 mEq/L). The recommended starting dose of Veltassa is 8.4 grams patiromer once daily. Privacy, Help Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or The objective of this analysis was to model the potential pharmacoeconomic value of using patiromer and spironolactone in patients with a history of hyperkalemia that prevents them from utilizing spironolactone. Certain patients with heart failure (HF) are unable to tolerate spironolactone therapy due to hyperkalemia. These patients on average had K 5.3 mEq/L. 2019 Dec 30;15:571-579. doi: 10.2147/VHRM.S210150. Results: Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Acute hyperkalemia is a clinical emergency that requires immediate treatment with the agents discussed below (TABLE 1).IV Calcium: IV calcium is indicated when the serum potassium is >6.5 mEq/L regardless of whether ECG changes are present.6 Given their poor sensitivity and specificity, ECG changes should not be used as diagnostic criteria for treatment of hyperkalemia.7 The immediate goal of acute management in hyperkalemi… is a member of the cation exchange resins drug class and is commonly used for Medication Lokelma (sodium zirconium cyclosilicate), Veltassa (patiromer) P&T Approval Date 6/2016, 6/2017, 8/2018, 12/2018, 3/2020 Effective Date 6/1/2020; Oxford only: 6/1/2020 1. 800-292-6363 Lokelma Oral Suspension. More information please phone: 866-494-8080 In the Donut Hole (also called the … Bertram Pitt reports serving as a consultant to Sanofi, Relypsa, Merck, Bayer, AstraZeneca, scPharmaceuticals, Tricida, KBP Biosciences, Stealth Peptides, Sarfez, and AuraSense; stock options in scPharmaceuticals, Tricida, KBP Biosciences, Sarfez, and AuraSense; serving on data safety monitoring committees for and receiving personal fees from Johnson & Johnson; and, in addition, he has a pending patent EFS ID 14916043, application number licensed to the University of Michigan School of Medicine. Co-Pay Range. How VELTASSA works— and keeps working VELTASSA binds to excess potassium in the colon and removes it from your body. 2010 May;14(24):1-162. doi: 10.3310/hta14240. The new potassium binders provide new efficacy and safety benefits, but, like all new innovation, come at a price. The placebo group had a mean reduction 0.3 mEq/L. 2018. FOIA Visit Website, Looking to reduce costs at the pharmacy counter? discounted medicines to low income or uninsured and under-insured people who meet specific guidelines. In the Typical co-pay stage, your deductible has been satisfied, and Medicare pays the majority of your drug costs. The green line represents the willingness-to-pay threshold of US$100,000 per QALY gained. Phase II and III clinical trials have indicated that patiromer and sodium zirconium cyclosilicate (ZS-9) have a dose-dependent ability to lower potassium levels. The circles represent health states, and each…, Tornado diagram of the incremental cost-effectiveness ratios changes between the patiromer–spironolactone–ACEI strategy and…, Cost-effectiveness acceptability curve. Lokelma is available as a brand name drug only, a generic version is not yet available. People who are in Medicare and may be eligible for the Limited Income Subsidy can apply. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. J Clin Pharm Ther. Pharmacoepidemiol Drug Saf. As the fastest growing pharmacy program in the country, Prescription Hope can obtain Veltassa for individuals at the set cost of $50.00 per month. Lokelma is not absorbed into the bloodstream. Prices are for cash paying customers only and are not valid with insurance plans. *See Additional Information section below, FDA Approved Diagnosis - See Program Website for Details. 2015. Monitor serum potassium and doi: 10.1111/j.1365-2710.2005.00694.x. Methods: Prog Cardiovasc Dis. We performed a cost-effectiveness analysis of treatment with patiromer, spironolactone, and an angiotensin-converting enzyme inhibitor (ACEI) in patients with New York Heart Association (NYHA) class III-IV HF compared with ACEI alone. Lokelma Prices. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. AZ gets US approval for Veltassa rival Lokelma. Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR. Curr Med Res Opin. Patiromer (VELTASSA ... (7.3%) vs. placebo (24.5%) experiencing hyperkalemia. One-way and probability sensitivity analyses were performed to test the robustness of the model findings. Contact program for more details: www.myaccess360.com. For instance, Lokelma is perceived by nephrologists to have a quicker onset of action compared to Veltassa, resulting in a 2 to 1 preference for Lokelma in hospitalized patients with hyperkalemia. 2016;32(1):155-64. doi: 10.1185/03007995.2015.1106935.